Literature DB >> 11566229

Multicenter evaluation of the novel enzyme immunoassay based on P1-enriched protein for the detection of Mycoplasma pneumoniae infection.

J Suni1, R Vainionpää, T Tuuminen.   

Abstract

The aim of the study was to evaluate new Mycoplasma pneumoniae IgG, IgA and IgM EIA methods based on the enrichment of P1-protein (ThermoLabsystems, Helsinki, Finland) (L) for the detection of acute infection. This evaluation was performed in two independent routine clinical microbiology laboratories. The first laboratory used samples preselected by IgG and IgM Platelia enzyme immunoassay (P) and the second used samples preseleced by Serion ELISA Classic M. pneumoniae IgG, IgM (V). The L method was also compared to the FDA approved method of ImmunoWell M. pneumoniae IgG and IgM (G). When the agreement of two methods was applied as a serologic criteria for an acute infection, the following ratios of acute to nonacute infection were calculated 32/86 (totally 118) in the first and 20/72 (totally 92) in the second laboratory. In the first laboratory, the corresponding ratios by methods were 35/83 (sensitivity 100%, specificity 96.5%), 31/87 (sensitivity 97%, specificity 100%), and 55/63 (sensitivity 100%, specificity 79%) for the L, P and G methods, respectively. In the second laboratory, the ratios were 21/71 (sensitivity 100%, specificity 99%), 16/76 (sensitivity 83%, specificity 100%), and 53/39 (sensitivity 100, specificity 69%) for the L, V and G methods, respectively. Taking into account that the tested sample material was preselected by the P and V methods, which may have introduced some bias in their favor, the newly developed L method utilizing P1-enriched protein was found reliable for serodiagnosis of acute M. pneumoniae infection. The method G was the least specific in detection of acute infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566229     DOI: 10.1016/s0167-7012(01)00291-3

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  6 in total

1.  Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Authors:  Matthias F C Beersma; Kristien Dirven; Alje P van Dam; Kate E Templeton; Eric C J Claas; Herman Goossens
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

2.  Eosinophilic Fasciitis associated with Mycoplasma arginini infection.

Authors:  Pálma Silló; Dóra Pintér; Eszter Ostorházi; Mercedes Mazán; Norbert Wikonkál; Katinka Pónyai; Dmitriy V Volokhov; Vladimir E Chizhikov; Susan Szathmary; Laszlo Stipkovits; Sarolta Kárpáti
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

Review 3.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

4.  Identification of an N-terminal 27 kDa fragment of Mycoplasma pneumoniae P116 protein as specific immunogen in M. pneumoniae infections.

Authors:  Irum Tabassum; Rama Chaudhry; Bishwanath Kumar Chourasia; Pawan Malhotra
Journal:  BMC Infect Dis       Date:  2010-12-13       Impact factor: 3.090

5.  Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.

Authors:  Hélène Nuyttens; Camille Cyncynatus; Hélène Renaudin; Sabine Pereyre; Cécile Bébéar
Journal:  BMC Microbiol       Date:  2010-08-11       Impact factor: 3.605

6.  Pediatric clinical features of Mycoplasma pneumoniae infection are associated with bacterial P1 genotype.

Authors:  Liping Fan; Dong Li; Liqiong Zhang; Chuangli Hao; Huiquan Sun; Xuejun Shao; Jun Xu; Zhengrong Chen
Journal:  Exp Ther Med       Date:  2017-07-09       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.